Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

Dr. Shiri Shulman from Assuta discusses the importance of continuity in treatment during wartime and innovative therapies ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...

Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the ...